Hengrui Pharmaceutical announced that its subsidiary Guangdong Hengrui Pharmaceutical Co., Ltd. has received the “Drug Clinical Trial Approval Notice” for SHR-1905 injections from the State Drug Administration and will conduct clinical trials in the near future. SHR-1905 injection is a thymic matrix lymphopoietin monoclonal antibody. It can block the release of inflammatory cytokines, improve inflammatory conditions, and control disease progression. Currently, similar products, Tezepelumab, have been approved for listing around the world. Up to now, SHR-1905 injection-related projects have invested a total of about 122 million yuan in R&D expenses.

Zhitongcaijing · 09/29 08:09
Hengrui Pharmaceutical announced that its subsidiary Guangdong Hengrui Pharmaceutical Co., Ltd. has received the “Drug Clinical Trial Approval Notice” for SHR-1905 injections from the State Drug Administration and will conduct clinical trials in the near future. SHR-1905 injection is a thymic matrix lymphopoietin monoclonal antibody. It can block the release of inflammatory cytokines, improve inflammatory conditions, and control disease progression. Currently, similar products, Tezepelumab, have been approved for listing around the world. Up to now, SHR-1905 injection-related projects have invested a total of about 122 million yuan in R&D expenses.